Reinforced Polymer–Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Giovanni Bovone und 17 weiteren Autor:innen. Beteiligte Einrichtung: Macromolecular Engineering Laboratory, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, 8092, Switzerland. Hauptthemen laut MEDLINE: Trastuzumab, Hydrogels, Nanoparticles, Polymers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In oncology, the advent of monoclonal antibody (mAb) therapeutics represents a breakthrough in various cancer diseases. However, these therapies often necessitate iterative hospital visits for intravenous infusion that alter patient quality of life and contribute to the chronic saturation of hospitals. Subcutaneous formulations of mAbs offer a promising alternative facilitating faster administration compared with traditional intravenous methods, while still maintaining the same dosing schedule and providing time‐saving advantages. Here, an injectable mAb delivery platform using α‐cyclodextrin (αCD)‐reinforced polymer–nanoparticle hydrogels to perform subcutaneous mAb depots and delay their release is developed. By leveraging mAb–polymer electrostatic complexation, hyaluronic acid‐ and alginate‐based injectable drug depots are formulated by simply mixing components that are generally regarded as safe. Trastuzumab is included as a clinically relevant therapeutic antibody. These formulations delayed mAb release both in vitro and in vivo mice models, with a similar pharmacokinetic performance to the clinically approved Herceptin SC (Roche) formulation composed of trastuzumab with recombinant human hyaluronidase (rHuPH20).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Macromolecular Engineering Laboratory, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, 8092, Switzerland.
- Nanomedicine laboratory, Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
- Strasbourg Drug Discovery and Development Institute (IMS), University of Strasbourg, Strasbourg, 67000, France.
- Equipe labellisée Ligue contre le cancer.
- Tumour Biomechanics lab, INSERM UMR_S1109, University of Strasbourg, Strasbourg, 67000, France.
- Radiation Oncology Department, Georges François Leclerc Cancer Center, Unicancer, Dijon, 21000, France.
ORCID-Profile: Giovanni Bovone, Stéphane Bernhard, Vincent Mittelheisser, Elia A Guzzi, Lorenza Garau Paganella, Mark W Tibbitt, Alexandre Detappe
Zitieren
APA
Bovone, G., Bernhard, S., Jacquot, G., Mittelheisser, V., Mirjolet, C., Guzzi, E. A., Paganella, L. G., Liebi, L., Draussin, J., Lopez Navarro, P., Barbé, E., Lefebvre, O., Goetz, J. G., Charbonnière, L. J., Pivot, X., Harlepp, S., Tibbitt, M. W., & Detappe, A. (2025). Reinforced Polymer–Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404660
Vancouver
Bovone G, Bernhard S, Jacquot G, Mittelheisser V, Mirjolet C, Guzzi EA, et al. Reinforced Polymer–Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404660
BibTeX
@article{Bovone2025,
author = {Bovone, Giovanni and Bernhard, Stéphane and Jacquot, Guillaume and Mittelheisser, Vincent and Mirjolet, Céline and Guzzi, Elia A and Paganella, Lorenza Garau and Liebi, Luca and Draussin, Julien and Lopez Navarro, Pedro and Barbé, Elsa and Lefebvre, Olivier and Goetz, Jacky G and Charbonnière, Loic J and Pivot, Xavier and Harlepp, Sébastien and Tibbitt, Mark W and Detappe, Alexandre},
title = {Reinforced Polymer–Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404660}
}
EUVIMED